Trials / Terminated
TerminatedNCT00242541
Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
Open Label Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of octreotide acetate to decrease GH and IGF-I levels in acromegalic patients, with microadenomas (≤ 10 mm) or macroadenomas (\> 10 mm).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide acetate |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2005-08-01
- First posted
- 2005-10-20
- Last updated
- 2012-04-26
Locations
1 site across 1 country: Mexico
Source: ClinicalTrials.gov record NCT00242541. Inclusion in this directory is not an endorsement.